274 related articles for article (PubMed ID: 20815453)
1. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.
Dille MF; McMillan GP; Reavis KM; Jacobs P; Fausti SA; Konrad-Martin D
J Acoust Soc Am; 2010 Sep; 128(3):1163-74. PubMed ID: 20815453
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
3. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
4. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
6. Distortion-product otoacoustic emission test performance for ototoxicity monitoring.
Reavis KM; McMillan G; Austin D; Gallun F; Fausti SA; Gordon JS; Helt WJ; Konrad-Martin D
Ear Hear; 2011 Feb; 32(1):61-74. PubMed ID: 20625302
[TBL] [Abstract][Full Text] [Related]
7. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
[TBL] [Abstract][Full Text] [Related]
8. [Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia].
Lisowska G; Namysłowski G; Hajduk A; Polok A; Tomaszewska R; Misiołek M
Otolaryngol Pol; 2006; 60(3):415-20. PubMed ID: 16989457
[TBL] [Abstract][Full Text] [Related]
9. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
Knight KR; Kraemer DF; Winter C; Neuwelt EA
J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
[TBL] [Abstract][Full Text] [Related]
10. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
Dhooge I; Dhooge C; Geukens S; De Clerck B; De Vel E; Vinck BM
Int J Audiol; 2006 Jun; 45(6):337-43. PubMed ID: 16777780
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of distortion-product otoacoustic emissions-based ototoxicity monitoring using various primary frequency step-sizes.
McMillan GP; Konrad-Martin D; Dille MF
Int J Audiol; 2012 Sep; 51(9):689-96. PubMed ID: 22676700
[TBL] [Abstract][Full Text] [Related]
12. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
13. Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals.
Sockalingam R; Freeman S; Cherny TL; Sohmer H
Am J Otol; 2000 Jul; 21(4):521-7. PubMed ID: 10912698
[TBL] [Abstract][Full Text] [Related]
14. [Effect of inner ear hearing loss on delayed otoacoustic emissions (TEOAE) and distortion products (DPOAE)].
Hoth S
Laryngorhinootologie; 1996 Dec; 75(12):709-18. PubMed ID: 9081275
[TBL] [Abstract][Full Text] [Related]
15. Effects of aspirin on distortion product fine structure: interpreted by the two-source model for distortion product otoacoustic emissions generation.
Rao A; Long GR
J Acoust Soc Am; 2011 Feb; 129(2):792-800. PubMed ID: 21361438
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin ototoxicity in the Sprague Dawley rat evaluated by distortion product otoacoustic emissions.
Hatzopoulos S; Di Stefano M; Campbell KC; Falgione D; Ricci D; Rosignoli M; Finesso M; Albertin A; Previati M; Capitani S; Martini A
Audiology; 2001; 40(5):253-64. PubMed ID: 11688544
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a cisplatin dose-ototoxicity model.
Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
[TBL] [Abstract][Full Text] [Related]
18. Detection of hearing loss using 2f2-f1 and 2f1-f2 distortion-product otoacoustic emissions.
Fitzgerald TS; Prieve BA
J Speech Lang Hear Res; 2005 Oct; 48(5):1165-86. PubMed ID: 16411804
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.
Konrad-Martin D; James KE; Gordon JS; Reavis KM; Phillips DS; Bratt GW; Fausti SA
J Am Acad Audiol; 2010 May; 21(5):301-14; quiz 357. PubMed ID: 20569665
[TBL] [Abstract][Full Text] [Related]
20. Repeatability of high-frequency distortion-product otoacoustic emissions in normal-hearing adults.
Dreisbach LE; Long KM; Lees SE
Ear Hear; 2006 Oct; 27(5):466-79. PubMed ID: 16957498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]